Insider Selling: Liquidia Co. (NASDAQ:LQDA) Insider Sells 2,526 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the sale, the insider now owns 204,857 shares in the company, valued at approximately $2,292,349.83. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Monday, October 14th, Rajeev Saggar sold 2,260 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60.

Liquidia Trading Up 1.3 %

Shares of LQDA stock traded up $0.14 during trading hours on Tuesday, reaching $11.23. 492,364 shares of the company’s stock were exchanged, compared to its average volume of 1,001,540. The stock’s fifty day moving average price is $10.39 and its two-hundred day moving average price is $11.86. The stock has a market cap of $858.13 million, a PE ratio of -7.07 and a beta of 0.22. Liquidia Co. has a 1 year low of $6.04 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The firm had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, equities analysts expect that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Monday, August 19th. Bank of America cut their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Scotiabank initiated coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Finally, BTIG Research decreased their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Patient Square Capital LP acquired a new position in Liquidia in the first quarter valued at approximately $105,942,000. Vanguard Group Inc. raised its stake in shares of Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after buying an additional 43,352 shares during the period. Farallon Capital Management LLC acquired a new position in shares of Liquidia during the 1st quarter worth approximately $30,311,000. Whitefort Capital Management LP raised its stake in shares of Liquidia by 45.8% during the 1st quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock worth $4,980,000 after buying an additional 106,049 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Liquidia by 119.4% during the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after buying an additional 125,315 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).